이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
WuXi Biologics (Cayman) 미래 성장
Future 기준 확인 3/6
WuXi Biologics (Cayman) (는) 각각 연간 13.9% 및 12.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.2% 로 예상됩니다.
주요 정보
13.7%
수익 성장률
13.2%
EPS 성장률
| Life Sciences 수익 성장 | 22.9% |
| 매출 성장률 | 12.8% |
| 향후 자기자본 수익률 | 10.2% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 24 Jun 2024 |
최근 미래 성장 업데이트
Recent updates
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease
Aug 02Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Jun 29What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
May 16Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today
May 03수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 24,138 | 5,436 | 2,046 | 7,130 | 23 |
| 12/31/2025 | 21,158 | 4,697 | 2,604 | 6,595 | 28 |
| 12/31/2024 | 18,119 | 3,848 | 391 | 5,934 | 25 |
| 12/31/2023 | 17,034 | 3,400 | 612 | 4,668 | N/A |
| 9/30/2023 | 16,794 | 3,776 | N/A | N/A | N/A |
| 6/30/2023 | 16,554 | 4,152 | N/A | N/A | N/A |
| 3/31/2023 | 15,911 | 4,286 | N/A | N/A | N/A |
| 12/31/2022 | 15,269 | 4,420 | -327 | 5,542 | N/A |
| 9/30/2022 | 14,179 | 4,251 | N/A | N/A | N/A |
| 6/30/2022 | 13,090 | 4,081 | -1,028 | 4,091 | N/A |
| 3/31/2022 | 11,690 | 3,735 | -2,052 | 3,761 | N/A |
| 12/31/2021 | 10,290 | 3,388 | -3,077 | 3,431 | N/A |
| 9/30/2021 | 9,183 | 3,092 | -4,006 | 2,840 | N/A |
| 6/30/2021 | 8,075 | 2,795 | -4,936 | 2,249 | N/A |
| 3/31/2021 | 6,844 | 2,242 | -4,540 | 2,065 | N/A |
| 12/31/2020 | 5,612 | 1,689 | -4,144 | 1,881 | N/A |
| 9/30/2020 | 4,967 | 1,494 | -4,049 | 1,649 | N/A |
| 6/30/2020 | 4,321 | 1,300 | -3,954 | 1,417 | N/A |
| 3/31/2020 | 4,152 | 1,157 | -2,979 | 1,312 | N/A |
| 12/31/2019 | 3,984 | 1,014 | -2,004 | 1,208 | N/A |
| 9/30/2019 | 3,535 | 922 | -1,356 | 1,035 | N/A |
| 6/30/2019 | 3,087 | 831 | -708 | 861 | N/A |
| 3/31/2019 | 2,811 | 731 | -810 | 811 | N/A |
| 12/31/2018 | 2,534 | 631 | -912 | 762 | N/A |
| 9/30/2018 | 2,277 | 520 | -1,004 | 508 | N/A |
| 6/30/2018 | 2,019 | 410 | -1,096 | 255 | N/A |
| 3/31/2018 | 1,819 | 331 | -712 | 308 | N/A |
| 12/31/2017 | 1,619 | 253 | -327 | 360 | N/A |
| 9/30/2017 | 1,429 | 177 | N/A | 320 | N/A |
| 6/30/2017 | 1,233 | 149 | N/A | 369 | N/A |
| 3/31/2017 | 1,111 | 145 | N/A | 226 | N/A |
| 12/31/2016 | 989 | 141 | N/A | 82 | N/A |
| 9/30/2016 | 889 | 171 | N/A | 162 | N/A |
| 12/31/2015 | 557 | 45 | N/A | 107 | N/A |
| 12/31/2014 | 332 | 42 | N/A | 22 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: 2269 의 연간 예상 수익 증가율( 13.9% )이 saving rate( 2.2% 보다 높습니다. ).
수익 vs 시장: 2269 의 연간 수익( 13.9% ) Hong Kong 시장( 11.7% 보다 빠르게 성장할 것으로 예상됩니다. 11.7% 연간).
고성장 수익: 2269 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: 2269 의 수익(연간 12.8% ) Hong Kong 시장( 7.8% 보다 빠르게 성장할 것으로 예상됩니다. 7.8% 연간).
고성장 수익: 2269 의 수익(연간 12.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: 2269 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 10.2 %).